Literature DB >> 7688335

Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease.

A G Thomas1, J M Holly, F Taylor, V Miller.   

Abstract

Twenty nine children with Crohn's disease were studied before and after treatment with steroids or an elemental diet to assess the effect of disease activity and treatment on serum insulin like growth factor I (IGF-I), insulin like growth factor binding protein (IGFBP-1), and insulin concentrations. The median serum IGF-I concentration was lower in patients with active disease than in matched controls, and lower in stunted than well grown patients, but insulin and IGFBP-1 concentrations were not significantly different between any group. After four weeks of either treatment there was an increase in the median serum IGF-I concentration; this was greater in the steroid group than the elemental diet group. The median serum insulin concentration increased and median serum IGFBP-1 concentration decreased in the steroid treated group but not in the elemental diet group. These changes were accompanied by a greater and more sustained increase in energy intake in the steroid group. Despite this the median height velocity SD score was greater in the elemental diet group than in the steroid group.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688335      PMCID: PMC1374231          DOI: 10.1136/gut.34.7.944

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

Review 1.  Somatomedin-binding proteins: what role do they play in the growth process?

Authors:  S Cianfarani; J M Holly
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

2.  Severe growth retardation in children with inflammatory bowel disease.

Authors:  T D McCaffery; K Nasr; A M Lawrence; J B Kirsner
Journal:  Pediatrics       Date:  1970-03       Impact factor: 7.124

3.  Note on the assessment and classification of protein-energy malnutrition in children.

Authors:  J C Waterlow
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

4.  Effect of administered human growth hormone on growth retardation in inflammatory bowel disease.

Authors:  T D McCaffery; K Nasr; A M Lawrence; J B Kirsner
Journal:  Am J Dig Dis       Date:  1974-05

5.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-12       Impact factor: 3.791

6.  Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease.

Authors:  A Tenore; W F Berman; J S Parks; A M Bongiovanni
Journal:  J Clin Endocrinol Metab       Date:  1977-04       Impact factor: 5.958

7.  Insulin-like growth factor binding protein-1 levels in diabetic adolescents and their relationship to metabolic control.

Authors:  J M Holly; D B Dunger; J A Edge; C P Smith; T Chard; J A Wass
Journal:  Diabet Med       Date:  1990-08       Impact factor: 4.359

8.  Plasma somatomedin activity in protein calorie malnutrition.

Authors:  P S Mohan; K S Jaya Rao
Journal:  Arch Dis Child       Date:  1979-01       Impact factor: 3.791

9.  Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.

Authors:  J M Tanner; R H Whitehouse
Journal:  Arch Dis Child       Date:  1976-03       Impact factor: 3.791

10.  Nyctohemeral growth hormone levels in children with growth retardation and inflammatory bowel disease.

Authors:  R W Gotlin; R S Dubois
Journal:  Gut       Date:  1973-03       Impact factor: 23.059

View more
  17 in total

Review 1.  Chronic inflammatory bowel disease in children: a complex problem in management.

Authors:  J A Walker-Smith
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

Review 2.  Bone abnormalities in gastrointestinal and hepatic disease.

Authors:  F A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 3.  Therapy of Crohn's disease in childhood.

Authors:  R M Beattie
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

4.  Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children.

Authors:  Andrew Sawczenko; Omeia Azooz; Joanna Paraszczuk; Maja Idestrom; Nick M Croft; Martin O Savage; Anne B Ballinger; Ian R Sanderson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

Review 5.  Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

Authors:  Laurent Peyrin-Biroulet; Mathias Chamaillard; Florent Gonzalez; Elodie Beclin; Cecilia Decourcelle; Laurent Antunes; Jérôme Gay; Christel Neut; Jean-Frédéric Colombel; Pierre Desreumaux
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

Review 6.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

7.  Parenteral and enteral nutrition in gastrointestinal disease.

Authors:  A G Thomas
Journal:  Indian J Pediatr       Date:  1994 Nov-Dec       Impact factor: 1.967

8.  Adult height in patients with early onset of Crohn's disease.

Authors:  N Alemzadeh; L T M Rekers-Mombarg; M L Mearin; J M Wit; C B H W Lamers; R A van Hogezand
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

9.  Serum IGF-I and C-reactive protein in healthy black and white young men: the CARDIA male hormone study.

Authors:  Laura A Colangelo; Brian Chiu; Peter Kopp; Kiang Liu; Susan M Gapstur
Journal:  Growth Horm IGF Res       Date:  2009-01-12       Impact factor: 2.372

10.  Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease.

Authors:  Meena Thayu; Justine Shults; Jon M Burnham; Babette S Zemel; Robert N Baldassano; Mary B Leonard
Journal:  Inflamm Bowel Dis       Date:  2007-09       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.